HP, Lexicon Pharmaceuticals And 3 Stocks To Watch Heading Into Tuesday
Portfolio Pulse from Lisa Levin
HP Inc., Skyline Champion Corporation, Lexicon Pharmaceuticals, UP Fintech Holding Limited, and Box, Inc. are stocks to watch on Tuesday. HP and Box are expected to post quarterly earnings after the closing bell, while Skyline Champion and UP Fintech will release earnings before the markets open. Lexicon Pharmaceuticals reported FDA approval of INPEFA for heart failure treatment.
May 30, 2023 | 7:35 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Box, Inc. is expected to post a quarterly loss of 32 cents per share on revenue of $266.55 million after the closing bell.
Box's stock price may be impacted by its earnings report. However, the direction of the impact will depend on whether the company meets, exceeds, or misses expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
HP Inc. is expected to post quarterly earnings of 76 cents per share on revenue of $13.09 billion after the closing bell.
HP's stock price may be impacted by its earnings report. However, the direction of the impact will depend on whether the company meets, exceeds, or misses expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
Skyline Champion Corporation is expected to report earnings of 93 cents per share on revenue of $528.22 million for the latest quarter before the markets open.
Skyline Champion's stock price may be impacted by its earnings report. However, the direction of the impact will depend on whether the company meets, exceeds, or misses expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEUTRAL IMPACT
UP Fintech Holding Limited is expected to report quarterly earnings at 3 cents per share on revenue of $45.06 million before the markets open.
UP Fintech's stock price may be impacted by its earnings report. However, the direction of the impact will depend on whether the company meets, exceeds, or misses expectations.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Lexicon Pharmaceuticals reported FDA approval of INPEFA for the treatment of heart failure, causing its shares to jump 17.6% to $3.74 in after-hours trading.
The FDA approval of INPEFA for heart failure treatment is a significant positive development for Lexicon Pharmaceuticals, which has already caused its stock price to jump 17.6% in after-hours trading. This momentum may continue in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100